Compare Cytokinetics Inc (CYTK) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Payoneer Global Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: Cytokinetics Inc is far larger — about 3.5× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Payoneer Global Inc for 61 Days on average.
| CYTK | PAYO | |
|---|---|---|
Market Cap | $8.62B | $2.43B |
Volume | 2,594,626 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $87.26 | $7.18 |
52-Week Low | $54.76 | $4.27 |
Typical Hold Time | 19 Days | 61 Days |
Enterprise Value | $8.72B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Payoneer (PAYO) trades at $7.16, up 0.14% on the day, with a bullish technical signal from moving averages and a mixed earnings history including a Q2 2026 miss. Revenue grew to $821.16M in 2025, but net income declined to $73.19M, compressing margins. The company renewed its partnership with Etsy through 2029 and faces ongoing legal scrutiny regarding its proposed acquisition by Nuvei.
The outlook is cautious; while analyst consensus is 60% buy-rated and cash flow trends are positive, risks include earnings volatility, acquisition uncertainty, and competitive pressures. Investors should weigh strong institutional interest against execution challenges and margin pressures for medium-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
